Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 2.
doi: 10.1111/dom.70071. Online ahead of print.

Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial

Alina N Saidi  1   2 , Laura A M Konings  1   2 , Carmen A W Dietvorst  1   2 , Vivian D de Jong  3   4 , Willem Pieter Brouwer  5 , Aart-Jan van der Lelij  2 , Marco Alings  6 , Martien van Wenum  7 , Simone P Rauh  8 , Weiwei Xu  3 , Manuel Castro Cabezas  1   2   4
Affiliations

Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial

Alina N Saidi et al. Diabetes Obes Metab. .

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent among individuals with overweight or obesity and type 2 diabetes (T2DM), increasing the risk for liver-related and cardiovascular complications. Lifestyle changes to reduce body weight are the primary intervention to decrease the risk of MASLD and liver fibrosis. This study aimed to evaluate the impact of a pharmacological intervention with naltrexone/bupropion (NB) on hepatic steatosis and fibrosis risk in patients with T2DM using non-invasive tests.

Materials and methods: In this post hoc analysis of a 56-week, randomized, double-blind, placebo-controlled trial 505 adults with T2DM and overweight or obesity were randomized to either NB or placebo (2:1), both combined with structured lifestyle counselling. Hepatic outcomes were measured using the Hepatic Steatosis Index (HSI), Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5) and Fibrosis-4 (FIB-4) indices. Changes in liver-related indices were analysed by treatment arm and weight loss strata (<5%, ≥5%, ≥10%), and multivariable regression was used to identify predictors of hepatic improvement.

Results: At Week 56, the NB group achieved significantly greater body weight loss (-6.3 ± 7.2 kg vs. -2.5 ± 5.2 kg, p < 0.001). Lifestyle intervention with NB treatment compared with placebo significantly reduced HSI (-2.9 vs. -1.2, p < 0.001) and MAF-5 (-0.80 vs. -0.31, p = 0.003), while FIB-4 scores remained unchanged in both groups. The best improvements in HSI and MAF-5 were observed in those achieving ≥5% or ≥ 10% weight loss compared with those with <5% (all p < 0.001). Weight change correlated strongly with HSI reduction (r = 0.796, p < 0.001) and moderately with MAF-5 (r = 0.488, p < 0.001), but not with FIB-4 (r = 0.034, p = 0.590). Multiple regression analysis identified weight change as the strongest predictor of improvements in hepatic markers (HSI, MAF-5, ALT and AST), with no significant contributions from other factors.

Conclusion: Weight loss was the key driver of hepatic improvements in patients with T2DM and overweight or obesity. Treatment with NB resulted in significantly greater weight reduction and significantly greater improvements in HSI and MAF-5 compared with placebo, suggesting an added benefit for liver health.

Keywords: MASH; MASLD; liver fibrosis; liver steatosis; naltrexone‐bupropion; weight loss.

PubMed Disclaimer

References

REFERENCES

    1. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL‐EASD‐EASO clinical practice guidelines on the management of metabolic dysfunction‐associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492‐542. doi:10.1016/j.jhep.2024.04.031
    1. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842‐852. doi:10.1016/j.jhep.2023.04.036
    1. Osorio‐Conles Ó, Vega‐Beyhart A, Ibarzabal A, et al. A distinctive NAFLD signature in adipose tissue from women with severe obesity. Int J Mol Sci. 2021;22(19):10541. doi:10.3390/ijms221910541
    1. Michalopoulou E, Thymis J, Lampsas S, et al. The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment. J Clin Med. 2025;14(2):428. doi:10.3390/jcm14020428
    1. Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22:1999‐2010.e8. doi:10.1016/j.cgh.2024.03.006

LinkOut - more resources